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research brief

ASSESSING MATERNAL
AND NEWBORN HEALTH
COMMODITIES IN BANGLADESH

The UN Commission on Life-Saving Commodities for Women and Children aims
to increase access to 13 commodities in
50 countries. As part of this global effort,
the Population Council conducted a landscape analysis in Bangladesh to review
policies, guidelines, availability, and use
of these commodities.
The landscaping exercise had two objectives: 1) To
provide a comprehensive description of maternal
and newborn health (MNH) commodity issues
from policy to point of care; and 2) To engage
stakeholders in rolling out the UN Commission
recommendations.
Specifically, the goals of this study were to:
• Engage with national leaders to determine
national priorities and information gaps;
• Examine policies and guidelines that impact the
use of the 13 lifesaving commodities;
• Explore procurement mechanisms,
manufacturing capacity, availability of quality
assurance guidelines/policies, product packaging
policies, distribution mechanisms, cost to end
users, and financing;
• Examine access to, and availability of, the 13
lifesaving commodities in public facilities at the
district, sub-district, and community levels, and in
private drugstores;
• Assess stakeholders’ i nterest and participation
in ensuring access to commodities; and
• Stimulate discussion to identify policies for
increasing access and availability.

METHODS
This landscape assessment
exercise had three
components: In-depth
interviews, web searches,
and site visits. Twenty one
in-depth interviews with
representatives from the
Ministry of Health and
Family Welfare (MoH&FW),
professional associations,
development partners,
pharmaceuticals, and NGOs
complemented the searches
and provided greater detail.

Another study operationalized and assessed
the ability of community
facility health providers
to detect, prevent, and
treat pre-eclampsia and
eclampsia (PE/E), as well
as administer a single
loading dose of MgSO4
before referral to secondary facilities. See accompanying “Operationalizing
National Protocol for
Preventing and Managing
PE/E in Community Facilities in Bangladesh.”

Online searches for drug
manufacturers were
conducted at http://www.
bddrugs.com/, and individual
websites of pharmaceutical companies and the Directorate
General of Drug Administration (DGDA) at http://www.dgda.
gov.bd.
To validate the availability of the commodities, researchers
visited public facilities and private drugstores at the district,
sub-district, and community levels, and assessed which
of the 13 commodities were available, which were out of
stock, and how the drugs were stored (including humidity
and temperature control/refrigeration) the day of the visit.
Following data collection, policy makers, program
managers, regulators, pharmaceutical industry
representatives, and other stakeholders attended
a workshop to share and discuss the assessment
findings and identify priority activities to strengthen
the implementation of the UN Commission’s
recommendations.
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TABLE 1. BARRIERS AND IMPACT (GLOBAL)

Commodity

Examples of key barriers

Potential five-year impact

Maternal health commodities
1. Oxytocin - post-partum
haemorrhage (PPH)

Often poor quality

2. Misoprostol - post-partum
haemorrhage (PPH)

Not included in national essential
medicines lists

3. Magnesium sulphate (MgSO4) severe pre-eclampsia and eclampsia

Lack of demand by health workers

55,000 maternal lives saved

4. Injectable antibiotics - newborn
sepsis

Poor compliance by health workers

1.22 million neonatal lives saved

5. Antenatal corticosteroids (ANCs) preterm respiratory distress syndrome

Low awareness of product and impact

466,000 neonatal lives saved

6. Chlorhexidine - newborn cord care

Limited awareness and demand

422,000 neonatal lives saved

7. Resuscitation devices - newborn
asphyxia

Requires trained health workers

336,000 neonatal lives saved

Limited availability of child-friendly
product

1.56 million lives saved

Poor understanding of products by
mothers/caregivers

1.89 million lives saved

15,000 maternal lives saved

Newborn health commodities

Child health commodities
8. Amoxicillin - pneumonia
9. Oral rehydration salt (ORS) diarrhea
10. Zinc - diarrhea
Reproductive health commodities
11. Female condoms

Low awareness among women and
health workers

12. Contraceptive implants - family
planning/contraception

High cost

13. Emergency contraception

Low awareness among women

Almost 230,000 maternal deaths
averted

DISCLAIMER: *The table above was adapted from the Commissioner’s Report from UN Commission on Life-Saving
Commodities for Women and Children, September 2012. It provides estimates of how many lives could be saved if common
barriers were overcome and equitable access achieved for 13 lifesaving commodities. The numbers presented are draft
estimates meant to give a general overview of the barriers certain commodities face and the potential impact if these barriers
were surmounted. These draft estimates are based on a systematic analysis approach.
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FINDINGS
Drug policies and guidelines
An important component of the National Drug Policy (NDP)
is to ensure quality drugs are available and affordable.
The policy also requires that quality assurance measures
occur during manufacturing, transit, and storage, along
with testing at different time points before it reaches the
end user. All drugs, medicines, and other commodities
in final dosage forms that are manufactured, imported,
distributed, marketed, or consumed in the country must
be registered with the DGDA in the specific dosages and
strengths recommended by the Drug Control Committee.
The landscaping exercise found all 13 lifesaving
commodities, except female condoms, are registered but
not available in the specific dosages needed for particular
MNH conditions or indications. For example, MgSO4 is not
available as a single loading dose in community facilities.
Additionally, some drugs were out of stock and shortages
were reported. See Table 1 for more information.

Above: MNH drugs stored in a public facility. Below: Workshop participants. Photos by Population Council.

Interviews with policy makers and program mangers
suggest those responsible for implementing MNH policies
and services were unaware of specific commodity policies,
the UN Commission report, and its recommendations.
There appears to be a lack of coordination between
drugstore keepers and providers. As a result, providers
are not aware of which drugs and commodities are
available in facility stores. Also, many providers reported
not being able to estimate the consumption rate of drugs
and commodities in their facilities due to a lack of data.

Quality control and quality assurance
The NDP requires that each pharmaceutical company
have quality control and quality assurance systems,
which monitor the entire manufacturing process from
the acquisition of raw materials to its conversion into a
finished product. It also requires that all pharmaceutical
companies have documented standard operating
procedures based on World Health Organization
recommended guidelines for each product.
Findings from interviews with drug authorities and
pharmaceutical representatives reveal drug testing
laboratories have limited manpower and logistics capacity.
These quality control mechanisms can only test 30% of
the 3,500 products developed each year.

Logistics and ordering of supplies
The MoH&FW follows the World Bank procedure for
procuring drugs and commodities through an open
bidding process. The lowest bidder gets the order if
they have requisite qualifications and can fulfill the
specifications required in the tender. By this process,
MoH&FW gets the lowest price.

There are several domestic pharmaceutical manufacturers
producing most of the 13 commodities. The DGDA regulates
the prices of local products, and without its approval no
pharmaceutical company can fix the price of drugs or
commodities.
Pharmaceutical manufacturers generally teach correct
storage practices to distributors, but not to drugstores, and
as a result, a knowledge gap for proper storage remains in
community drugstores. Currently, there is no public private
partnership for pharmaceutical products.
Usually, drugs and commodities are ordered at the national
level, stored at central warehouses, and then distributed to
districts and facilities. At the sub-district level, there is no
scope for local procurement.
In facilities, most respondents were unaware of the
quality control and quality assurance guidelines. However,
pharmaceutical company representatives mentioned that
the DGDA quality assurance guidelines required them to
have their own standard operating procedures. They also
said end users are unwilling to pay for the drugs. This
low demand for oxytocin, misoprostol, MgSO4, antenatal
corticosteroids, zinc, and emergency contraceptive pills
serves as a disincentive to stock them.
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Private drugstores/pharmacies
Researchers visited 27 private drugstores and
pharmacies at all levels to determine the availability of
the drugs and commodities. Overall, the most available
drugs were amoxicillin, zinc, and oral rehydration salts.
However, oxytocin, misoprostol, and MgSO4 were less
available. Almost all drug sellers reported low demand
for them, as they require a doctor’s prescription and their
volume of sales depended on the extent to which doctors
prescribed them. Drugstore keepers explained that they
lose money if the drugs expired on the shelf due to low
sales, and so they do not stock them.

Packaging of product
Individual packaging for each of the 13 commodities
is unavailable. Many of them are available in universal
dosages, from which service providers must decide the
amount given for specific MNH indications. For example,
antibiotics for neonatal sepsis are available in various
dose forms of drop, suspension, tablet, and injection in
different concentrations. It is not specifically packaged
for neonatal sepsis, but simply mentioned as one of the
indications.
Similarly, MgSO4 is available in solution, but in different
concentrations. There is no separate packaging for a
loading dose of 10 mg in a vial. Available forms are
2.46 grams per 5 ml or 4 grams in per 100 ml vial,
which means four vials are required as a loading dose in
community facilities before referral.
No drug is included in existing bundles, such as the
delivery kit, but there are ongoing discussions about
this. The prospect of separate packaging had enormous
support from all respondents, as they felt separate
packaging of appropriate doses would help with proper
dosages for specific indications.

Financing
The government supplies all drugs and commodities
for free to providers in facilities or during doorstep
deliveries. However, in reality services and drugs at
the facilities are not free of cost, and end users have
considerable out of pocket expenses. They may have
to pay informal service fees or purchase drugs from
external sources.
Drug sellers feel that health expenditures and out of
pocket expenses in the market are within reach for
most end users. They also said there must be a safety
net provided for ultra-poor people. All respondents
felt products should be included in conditional cash
transfer coupons, vouchers, or other similar schemes,
particularly the ongoing public sector maternal health
voucher schemes.
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RECOMMENDATIONS
• Stronger advocacy with pharmaceutical companies to
manufacture a single loading dose of MgSO4 solution;
• Essential drugs and commodities should be available in
UH&FWCs, where normal vaginal deliveries are planned
and conducted;
• Formation of a forum at the Directorate General of
Family Planning (DGFP) to advocate access to, and use of,
MNH drugs and commodities;
• Further initiatives that ensure drug quality,
appropriateness of dosage, and reliable availability in the
private and public spheres; and
• DGDA, DGFP, and Directorate General of Health Services
should be updated regularly on global MNH and other
public health issues.
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